Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.
Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ; UK Dermatology Clinical Trials Network BLISTER Study Group. Williams HC, et al. Among authors: walton s. Lancet. 2017 Apr 22;389(10079):1630-1638. doi: 10.1016/S0140-6736(17)30560-3. Epub 2017 Mar 6. Lancet. 2017. PMID: 28279484 Free PMC article. Clinical Trial.
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, Schmidt E, Godec TR, Nunn AJ, Williams HC. Chalmers JR, et al. Among authors: walton s. Health Technol Assess. 2017 Mar;21(10):1-90. doi: 10.3310/hta21100. Health Technol Assess. 2017. PMID: 28406394 Free PMC article. Clinical Trial.
A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.
Chalmers JR, Wojnarowska F, Kirtschig G, Nunn AJ, Bratton DJ, Mason J, Foster KA, Whitham D, Williams HC; BLISTER study group. Chalmers JR, et al. Br J Dermatol. 2015 Jul;173(1):227-34. doi: 10.1111/bjd.13729. Epub 2015 May 26. Br J Dermatol. 2015. PMID: 25683592 Clinical Trial.
Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.
Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, Schmidt E, Harman K, Walton S, Chapman A, Williams HC; U.K. Dermatology Clinical Trials Network BLISTER Study Group. Mason JM, et al. Among authors: walton s. Br J Dermatol. 2018 Feb;178(2):415-423. doi: 10.1111/bjd.16006. Epub 2018 Jan 15. Br J Dermatol. 2018. PMID: 28940316 Free PMC article. Clinical Trial.
Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.
Holtsche MM, Goletz S, van Beek N, Zillikens D, Benoit S, Harman K, Walton S, English J, Sticherling M, Chapman A, Levell NJ, Groves R, Williams HC, König IR, Schmidt E; members of the BLISTER Study Group. Holtsche MM, et al. Among authors: walton s. Br J Dermatol. 2018 Oct;179(4):918-924. doi: 10.1111/bjd.16553. Epub 2018 Jul 5. Br J Dermatol. 2018. PMID: 29607480 Clinical Trial.
Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial.
Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC; UK Dermatology Clinical Trials Network’s STOP GAP Team. Ormerod AD, et al. Among authors: walton s. BMJ. 2015 Jun 12;350:h2958. doi: 10.1136/bmj.h2958. BMJ. 2015. PMID: 26071094 Free PMC article. Clinical Trial.
Generating new evidence, improving clinical practice and developing research capacity: the benefits of recruiting to the U.K. Dermatology Clinical Trials Network's STOP GAP and BLISTER trials.
Batchelor JM, Chapman A, Craig FE, Harman KE, Kirtschig G, Martin-Clavijo A, Ormerod AD, Walton S, Williams HC. Batchelor JM, et al. Among authors: walton s. Br J Dermatol. 2017 Nov;177(5):e228-e234. doi: 10.1111/bjd.15959. Epub 2017 Nov 10. Br J Dermatol. 2017. PMID: 29124728
749 results